The new data in pulmonary injury and emphysema provide "support for additional clinical applications of this drug, such as treatment of acute and chronic lung injury," according to a company official.
USPTO Publishes Three Patents, Six Patent Applications Related to RNAi
Under the deal, Bristol-Myers Squibb will use siRNAs formulated with Tekmira's stable nucleic acid-lipid particle-based delivery technology to "validate the function of certain cellular targets."
Safety data show no dose-limiting toxicities in any cohort, Quark said, supporting the drug's continued development.
The deal, which is independent of another arrangement under which Silence is developing siRNA drugs against AstraZeneca-specified targets, has been extended for one year.
According to MDRNA, the application claims siRNAs and delivery systems with therapeutic potential.
However, the company will most likely require an additional infusion of capital before it can move any of its programs into the clinic, Traversa President and CEO Hans Petersen said.
Under the expanded deal, Silence will demonstrate functional delivery of siRNAs against new targets selected by Dainippon.
The data, which appeared in the online edition of Nature, "demonstrate that RNAi can occur in a human from a systemically delivered siRNA, and that siRNA can be used as a gene-specific therapeutic," the investigators wrote.
Under the agreement, the companies will examine the ability of the PTD-DRBD technology to deliver siRNAs against undisclosed targets, with an eye toward developing RNAi therapeutics.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.